Caribou Biosciences
CRBU
About: Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
Employees: 147
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
49% more call options, than puts
Call options by funds: $170K | Put options by funds: $114K
12% more capital invested
Capital invested by funds: $46.5M [Q1] → $51.9M (+$5.5M) [Q2]
1% less funds holding
Funds holding: 130 [Q1] → 129 (-1) [Q2]
3% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 35
10.18% less ownership
Funds ownership: 54.03% [Q1] → 43.85% (-10.18%) [Q2]
37% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 43
50% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]
Financial journalist opinion
